A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas

In Vivo. 2018 May-Jun;32(3):597-602. doi: 10.21873/invivo.11281.

Abstract

Background/aim: The purpose of this study was to compare the clinical behavior of several grades of endometrioid carcinoma (EC) compared to high-grade serous carcinoma (HGSC), based on World Health Organization 2014 criteria.

Materials and methods: Clinicopathological features were compared between all grades of EC and HGSC, and between HGSC and either grade 1/2 or grade 3 EC.

Results: Sixty-five patients with EC and 214 with HGSC were identified. Among patients with EC, 56 displayed 1/2 EC and nine had grade 3 EC. The progression-free (PFS) and overall (OS) survival of patients with grade 1/2 EC were better than of those of patients with HGSC; however, PFS and OS did not statistically differ between patients with grade 3 EC and those with HGSC. Grade 1/2 EC, but not grade 3, was a better prognostic factor compared with HGSC.

Conclusion: A grading system for EC would be beneficial for the accurate prognosis of ovarian cancer.

Keywords: Ovarian endometrioid carcinoma; World Health Organization 2014 criteria; ovarian high-grade serous carcinoma; prognosis.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor
  • Endometrial Neoplasms / drug therapy
  • Endometrial Neoplasms / mortality*
  • Endometrial Neoplasms / pathology*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Grading / methods
  • Neoplasm Grading / standards
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / mortality*
  • Ovarian Neoplasms / pathology*
  • Practice Guidelines as Topic
  • Prognosis
  • Proportional Hazards Models
  • World Health Organization

Substances

  • Biomarkers, Tumor